UnitedHealth Group Incorporated (NYSE: UNH) is set to open Monday under significant pressure after Berkshire Hathaway revealed it had liquidated its entire stake in the health insurance giant during the first quarter. The disclosure, made late Friday, sent shares sliding after a week of gains, with the stock now facing a potentially volatile start to the trading week.
UnitedHealth shares closed the regular session at $393.85, down 1.31% on the day, but had posted a weekly gain of approximately 3.7% from the prior Friday's close of $379.98. The day's trading range spanned $390.25 to $397.63. In after-hours trading, however, the stock extended its losses, dropping further to $375.46 on lighter volume following the 4 p.m. ET close.
The timing of Berkshire's exit is particularly notable. UnitedHealth had been rallying on investor optimism that medical costs were beginning to ease for major insurers. However, Berkshire's filing indicated a familiar seller moving against that trade. The filing, which reflects holdings as of March 31, does not specify any actions taken after UnitedHealth's April earnings report. Reuters noted that the sale was part of a broader portfolio shift by Berkshire, which bought $15.94 billion in stocks and sold $24.09 billion in the first quarter.
Broader market conditions also weighed on sentiment. The S&P 500 fell 1.24% on Friday, while the Dow Jones Industrial Average declined 1.07%. Within the managed-care sector, performance was mixed: Humana rose 1.25%, while Elevance Health dropped 1.02%.
Medical cost pressure remains the central concern for investors. The medical care ratio, which measures the portion of premium revenue allocated to medical claims and care costs, has become increasingly critical as Medicare Advantage utilization has surged over the past three years, squeezing margins across the industry.
Analysts remain cautious. Morningstar's Julie Utterback told Reuters it is “a little early to call a victory.” UBS's AJ Rice noted that cost trends “appear to be stabilizing,” while Leerink Partners' Whit Mayo highlighted the second quarter as “the test.” UnitedHealth CFO Wayne DeVeydt acknowledged that investors will want to see “how April and May evolves” as first-quarter claims data come through.
UnitedHealth's April earnings update provided some support for bulls. The company reported first-quarter revenue of $111.7 billion and adjusted earnings of $7.23 per share, while raising its full-year 2026 adjusted earnings guidance above $18.25 per share. CEO Stephen Hemsley stated that UnitedHealth is focused on “simplify[ing] and moderniz[ing] health care.”
The risk remains clear: if second-quarter claims data reveal that lower first-quarter costs were due to a mild flu season or weather-delayed care, shares could lose more of their recent bounce. Berkshire's exit adds another layer of uncertainty, though the filing only captures positions as of late March.
Monday's price outlook remains uncertain, with a choppy path expected rather than a clear direction. Holding above Friday's regular-session low of $390.25 could keep targets at $400 and the $404.15 high from Wednesday in play. If prices break below that floor, the after-hours mark of $375.46 becomes the next key level. The true test, however, lies further out when investors gain clearer visibility on medical claims data from April and May.
